CORT

Despite the Nasdaq's tech-heavy composition, five non-tech Nasdaq-listed stocks with Zacks Rank #1 ratings are positioned for strong growth. Ross Stores plans 115 store openings with 13% Q2 sales growth, Roku's advertising revenue climbed 24.8%, APA Corp benefits from cost savings and long-term growth projects, Corcept Therapeutics sees strong drug demand with recent FDA approvals, and Halozyme generates royalties from pharma collaborations.

With September CPI rising 3.7% year-over-year and inflation concerns potentially triggering additional Fed rate hikes, the article recommends three low-beta defensive healthcare stocks: Cardinal Health (CAH), UnitedHealth Group (UNH), and Corcept Therapeutics (CORT). These stocks offer lower market volatility and strong earnings growth prospects in an uncertain economic environment.

Options traders are pricing in significant volatility for Corcept Therapeutics, with the November 20, 2026 $47.50 Put showing high implied volatility. The company holds a Zacks Rank #1 (Strong Buy) rating, and analysts have raised earnings estimates over the past 60 days, with consensus moving from 55 cents to 68 cents per share. High implied volatility may indicate traders are positioning for a major price move or preparing to sell premium.